These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 31362933)

  • 21. Precision Medicine for Heart Failure: Back to the Future.
    Feldman AM
    J Am Coll Cardiol; 2019 Mar; 73(10):1185-1188. PubMed ID: 30871702
    [No Abstract]   [Full Text] [Related]  

  • 22. Precision medicine in heart failure no longer a visual theory but a realistic opportunity.
    Sinagra G; Porcari A; Merlo M
    Eur J Intern Med; 2020 Jan; 71():20-22. PubMed ID: 31727453
    [No Abstract]   [Full Text] [Related]  

  • 23. Embracing the Long Road to Precision Medicine.
    Chirinos JA; Lanfear DE
    Circ Heart Fail; 2018 Jul; 11(7):e005089. PubMed ID: 29997241
    [No Abstract]   [Full Text] [Related]  

  • 24. Computer-aided biomarker discovery for precision medicine: data resources, models and applications.
    Lin Y; Qian F; Shen L; Chen F; Chen J; Shen B
    Brief Bioinform; 2019 May; 20(3):952-975. PubMed ID: 29194464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Personalized CHF treatment: PCT to guide therapy in heart failure patients.
    Lee NS; Daniels LB
    Int J Cardiol; 2014 Sep; 176(2):307-8. PubMed ID: 25115245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine.
    Polsinelli VB; Shah SJ
    Expert Opin Pharmacother; 2017 Mar; 18(4):399-409. PubMed ID: 28129699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induced Pluripotent Stem Cell (iPSC)-Derived Exosomes for Precision Medicine in Heart Failure.
    Yang PC
    Circ Res; 2018 Mar; 122(5):661-663. PubMed ID: 29496797
    [No Abstract]   [Full Text] [Related]  

  • 28. Genotype-phenotype correlations in ARVC: Toward a precision medicine approach.
    Addison J; Taylor MRG; Mestroni L
    Int J Cardiol; 2019 Jul; 286():115-116. PubMed ID: 30898427
    [No Abstract]   [Full Text] [Related]  

  • 29. IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure.
    Januzzi JL; Packer M; Claggett B; Liu J; Shah AM; Zile MR; Pieske B; Voors A; Gandhi PU; Prescott MF; Shi V; Lefkowitz MP; McMurray JJV; Solomon SD
    Circ Heart Fail; 2018 Oct; 11(10):e005133. PubMed ID: 30354399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcriptome of blood cells as a reservoir of cardiovascular biomarkers.
    Devaux Y
    Biochim Biophys Acta Mol Cell Res; 2017 Jan; 1864(1):209-216. PubMed ID: 27836747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer Biomarker Discovery for Precision Medicine: New Progress.
    Zou J; Wang E
    Curr Med Chem; 2019; 26(42):7655-7671. PubMed ID: 30027846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neprilysin and Natriuretic Peptide Regulation in Heart Failure.
    Bayes-Genis A; Morant-Talamante N; Lupón J
    Curr Heart Fail Rep; 2016 Aug; 13(4):151-7. PubMed ID: 27260315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neprilysin and Heart Failure: A "Sympathetic" Relationship?
    Pascual-Figal DA
    J Am Coll Cardiol; 2017 Oct; 70(17):2154-2156. PubMed ID: 29050563
    [No Abstract]   [Full Text] [Related]  

  • 34. Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview.
    Shah SJ
    J Cardiovasc Transl Res; 2017 Jun; 10(3):233-244. PubMed ID: 28585183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarkers: Delivering on the expectation of molecularly driven, quantitative health.
    Wilson JL; Altman RB
    Exp Biol Med (Maywood); 2018 Feb; 243(3):313-322. PubMed ID: 29199461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Precision Transplant Medicine: Biomarkers to the Rescue.
    Naesens M; Anglicheau D
    J Am Soc Nephrol; 2018 Jan; 29(1):24-34. PubMed ID: 28993504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neprilysin Inhibitors: Filling a Gap in Heart Failure Management, Albeit Amidst Controversy and at a Significant Cost.
    Manolis AS; Manolis TA; Manolis AA; Melita H
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):21-36. PubMed ID: 29926350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity.
    Packer M
    Circulation; 2018 Apr; 137(15):1614-1631. PubMed ID: 29632154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Barcelona Bio-HF Calculator Version 2.0: incorporation of angiotensin II receptor blocker neprilysin inhibitor (ARNI) and risk for heart failure hospitalization.
    Lupón J; Simpson J; McMurray JJV; de Antonio M; Vila J; Subirana I; Barallat J; Moliner P; Domingo M; Zamora E; Bayes-Genis A
    Eur J Heart Fail; 2018 May; 20(5):938-940. PubMed ID: 28949101
    [No Abstract]   [Full Text] [Related]  

  • 40. Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure.
    Prenner SB; Shah SJ; Yancy CW
    Curr Atheroscler Rep; 2016 Aug; 18(8):48. PubMed ID: 27324636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.